Issuer’s Business, Products and Services
The purpose of this section is to provide a clear description of the issuer’s current operations. In answering this item,
please include the following:
A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)
1. Elto Pharma, Inc.: 45 Wall Street, Suite 920, New York, NY 10005
a. 50.1%-owned by Amarantus
b. Gerald Commissiong, CEO and sole director
2. Cutanogen Corporation: 45 Wall Street, Suite 920, New York, NY10005
a. Gerald Commissiong, CEO and sole director
b. 90.1% owned by Amarantus
3. MANF Therapeutics, Inc.: 45 Wall Street, Suite 920, New York, NY 10005
a. Gerald Commissiong, CEO and sole director
b. 100% owned by Amarantus.
4. Theralink Technologies (f/k/a Avant Diagnostics, Inc.): 1050 30th St NW, Suite 107,
Washington, DC 20007
a. Mick Ruxin, MD, CEO
b. 31.5% prior to completion of corporate restructuring of Theralink Technologies, which is in
progress. The restructuring will likely result in a dilution of the Company’s ownership.
5. AMBS Operations LLC: 45 Wall Street, Suite 920, New York, NY 10005
a. Gerald Commissiong, Manager
b. 100% owned by Amarantus
6. Hemp BioHealth LLC: 45 Wall Street, Suite 920, New York, NY 10005
a. Gerald Commissiong, Manager
b. 100% owned by Amarantus
7. Hempori, Inc. 17481 Preston Road, Dallas, TX 75252
51% Owned by Amarantus

https://www.otcmarkets.com/otcapi/company/fin...96/content